Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhPRG4 in Ocular Graft-Versus-Host Disease
NCT07118254Phase 2Recruiting
- Sponsor
- Lubris BioPharma
- Start
- Sep 2025
- Primary completion
- Mar 2027
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human proteoglycan 4 in ocular graft-versus-host disease (oGVHD), sponsored by Lubris BioPharma. Started Sep 2025; status: recruiting.
02
Drugs
recombinant human proteoglycan 4
03
Conditions
ocular graft-versus-host disease (oGVHD)
Beyond the preview
Go deeper on NCT07118254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07118254.